BUZZ-Nuvalent jumps after GSK's $10.6 bln acquisition deal

Nuvalent, Inc. Class A
GlaxoSmithKline plc Sponsored ADR

Nuvalent, Inc. Class A

NUVL

0.00

GlaxoSmithKline plc Sponsored ADR

GSK

0.00

** Shares of cancer drugmaker Nuvalent NUVL.O jump 38.4% to $122.56 premarket

** Drugmaker GSK GSK.L agrees to buy NUVL for $10.6 bln

** The all-cash deal values NUVL at $124 per share, a 40% premium to its Monday's closing price of $88.49

** Deal is expected to close in the third quarter of 2026

** GSK shares down 3.5% at 1,846 p

** Up to last close NUVL shares were down ~12%, YTD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.